Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of in-hospital outcomes with low-dose fibrinolytic therapy followed by urgent percutaneous coronary intervention versus percutaneous coronary intervention alone for treatment of ST-elevation myocardial infarction.
Bhatt NS, Solhpour A, Balan P, Barekatain A, McCarthy JJ, Sdringola S, Denktas AE, Smalling RW, Anderson HV. Bhatt NS, et al. Among authors: solhpour a. Am J Cardiol. 2013 Jun 1;111(11):1576-9. doi: 10.1016/j.amjcard.2013.01.326. Epub 2013 Mar 12. Am J Cardiol. 2013. PMID: 23490028
Comparison of outcomes for patients ≥75 years of age treated with pre-hospital reduced-dose fibrinolysis followed by percutaneous coronary intervention versus percutaneous coronary intervention alone for treatment of ST-elevation myocardial infarction.
Solhpour A, Chang KW, Balan P, Cai C, Sdringola S, Denktas AE, Smalling RW, Anderson HV. Solhpour A, et al. Am J Cardiol. 2014 Jan 1;113(1):60-3. doi: 10.1016/j.amjcard.2013.09.017. Epub 2013 Oct 3. Am J Cardiol. 2014. PMID: 24207074
Comparison of 30-day mortality and myocardial scar indices for patients treated with prehospital reduced dose fibrinolytic followed by percutaneous coronary intervention versus percutaneous coronary intervention alone for treatment of ST-elevation myocardial infarction.
Solhpour A, Chang KW, Arain SA, Balan P, Zhao Y, Loghin C, McCarthy JJ, Vernon Anderson H, Smalling RW. Solhpour A, et al. Catheter Cardiovasc Interv. 2016 Nov;88(5):709-715. doi: 10.1002/ccd.26523. Epub 2016 Mar 29. Catheter Cardiovasc Interv. 2016. PMID: 27028120
Cardiac amyloidosis.
Yusuf SW, Solhpour A, Banchs J, Lopez-Mattei JC, Durand JB, Iliescu C, Hassan SA, Qazilbash MH. Yusuf SW, et al. Among authors: solhpour a. Expert Rev Cardiovasc Ther. 2014 Feb;12(2):265-77. doi: 10.1586/14779072.2014.876363. Epub 2014 Jan 6. Expert Rev Cardiovasc Ther. 2014. PMID: 24386926 Review.
Atorvastatin Effect on COVID-19 Outcomes: A Propensity Score Matched Study on Hospitalized Patients.
Pourhoseingholi MA, Yazdani O, Azizmohammad Looha M, Safavi-Naini SAA, Esbati R, Ilkhani S, Taraghikhah N, Hatamabadi H, Sadeghi A, Heidari K, Namazi N, Asadimanesh N, Hatari S, Shahrokh S, Solhpour A, Jamialahmadi T, Santos RD, Sahebkar A. Pourhoseingholi MA, et al. Among authors: solhpour a. Curr Med Chem. 2024 Jan 21. doi: 10.2174/0109298673264305231025093939. Online ahead of print. Curr Med Chem. 2024. PMID: 38251698
40 results